Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Cellectis Nom. buy spalato buy

34,75 €
50,00 €
Rendite (%)
-16,55 %
29,00 €
Diese Einschätzung wurde am 14.09.15 mit einem Endkurs von 29,00 € beendet. Mit einer Rendite von -16,55 % entwickelte sich die Einschätzung BUY nicht nach Plan.

Kommentare von spalato zu dieser Einschätzung

In der Diskussion Trading Cellectis Nom.

Geschrieben am 14.09.15
Einschätzung Buy
Kursziel 50,00

(Laufzeit überschritten)

In der Diskussion Cellectis Nom. diskutieren

Geschrieben am 12.03.15
Einschätzung Buy
Kursziel 50,00

Sehr interresant

ellectis is an international pharmaceutical company headquartered in Paris, France. It is focused on developing and offering immunotherapies based on gene-edited CAR-T cells (UCART). Unlike other companies in the CAR-T space, Cellectis offers allogeneic CAR-T cells, which allows it to produce an off-the-shelf alternative. The company plans to utilize its validated genome-editing technology to delete the T-cell receptor (TCR) from CAR-T cells. By deleting the TCR, the CAR-T cells are no longer able to detect "non-self", thus theoretically allowing T-cells from unrelated donors to be transplanted into recipients without the risk of graft-versus-host disease. This allogeneic cell production can be standardized and controlled, while autologous cells cannot, because they are sampled from individual patients. The company has a Phase I clinical trial using anti-CD19 CAR-T cells to treat ALL and CLL planned to start in Q2 2015.

Cellectis has two major big pharma partners - Servier Laboratories and Pfizer (NYSE:PFE), which provide clinical and regulatory expertise. Under the Pfizer collaboration announced in June 2014, Cellectis received $80M, funding for Pfizer-selected CAR-T targets, and up to $185M in milestones from eachcandidate Pfizer develops (~12 targets), and then finally, tiered royalties on any future sales. The cash and support from the Servier/Pfizer partnerships serve to buffer both financial and development risks moving forward. Cellectis currently has a market cap of $803.74M, $20.21M in cash, and a quarterly burn of $2M.